June 2004
Clinical Infectious Diseases;6/1/2004, Vol. 38 Issue 11, p3
Academic Journal
A high-security laboratory has grown a prototype H5N1 bird flu virus, which is a first step toward making a human vaccine against the potentially deadly new pathogen. The clinical trials are expected to take several months, but large-scale vaccine production would only begin if a pandemic broke out. Clinical trials will be conducted in the United States, under the sponsorship of the U.S. National Institutes of Health. The World Health Organization will give the prototype virus three drug makers who have expressed interest in producing small sample vaccine batches and carrying out clinical trials.


Related Articles

  • How might acupuncture work? A systematic review of physiologic rationales from clinical trials. Moffet, Howard H. // BMC Complementary & Alternative Medicine;2006, Vol. 6, p25 

    Background: Scientific interest in acupuncture has led numerous investigators to conduct clinical trials to test the efficacy of acupuncture for various conditions, but the mechanisms underlying acupuncture are poorly understood. Methods: The author conducted a PubMed search to obtain a fair...

  • REVOKING LEUKEMIA'S LICENSE TO KILL. Netting, Jessa Forte // Discover;Mar2005, Vol. 26 Issue 3, p9 

    Provides information on clinical trials conducted on a vaccine for treating leukemia. Mechanism of action; Overview of myelogenous leukemia.

  • Formulary considerations.  // Formulary;Feb2006, Vol. 41 Issue 2, p73 

    The article focuses on Dalbavancin, a long-acting lipoglycopeptide antibiotic of Pfizer Inc. The antibiotic is currently in phase 3 clinical trials for the treatment of resistant gram-positive pathogens. The mechanism by which the agent exerts its bacterial activity by binding to the terminal...

  • Role of antibiotics in generalized aggressive periodontitis: A review of clinical trials in humans. Ahuja, Annapurna; Baiju, C. S.; Ahuja, Vipin // Journal of Indian Society of Periodontology;Jul-Sep2012, Vol. 16 Issue 3, p317 

    Background: It is well-recognized fact that periodontal diseases are caused by multifactorial etiologies, in which microorganisms play an important role. An essential component of therapy is to eliminate or manage these pathogens. This has been traditionally accomplished through mechanical means...

  • Comment from Sarah Sleet - Chief Executive - Coeliac UK.  // Foods Matter (USA);Nov2008, p5 

    The author comments on the results of the clinical trials for the treatment of coeliac disease. She states that she is interested in the fact that there is a potential in the results of the trials, however, it is important to stress that there is still no pill and that a vaccine in not yet...

  • Taking the Bite Out of Rabies.  // Time;12/27/1976, Vol. 108 Issue 26, p66 

    The article reports that the anti-rabies vaccine developed by the U.S. and Iranian doctors has passed the second test in West Germany. It states that the patients, who have been biten by rapid animals have not developed rabies or showed sever allergic reaction after being administered with the...

  • Patients support innovative models of care in recurrent genital herpes clinics: results from a patient satisfaction study. Hamill, M.; Goldmeier, D. // International Journal of STD & AIDS;Sep2005, Vol. 16 Issue 9, p615 

    Genital herpes is one of the most common sexually transmitted infections and is characterized by recurrent, painful, ulcerative lesions. Severe psychosocial disturbance has been described in a variety of settings and there are well-documented associations with poor self-esteem, centred around...

  • Promising SARS Vaccine. Hampton, Tracy // JAMA: Journal of the American Medical Association;8/25/2004, Vol. 292 Issue 8, p916 

    Reports on a promising nasal spray vaccine for SARS. How the experimental vaccine was designed by the National Institute of Allergy and Infectious Diseases; Belief the spray is ready for clinical trials; Evidence that the vaccine strain has been shown safe in children.

  • Vical Flies High on Bird Flu Vaccine News. Chambers, Heather // San Diego Business Journal;2/23/2009, Vol. 30 Issue 8, p10 

    The article reports on the results of Vical Inc.'s experimental pandemic bird flu vaccine, Vaxfectin. Vical released that Vaxfectin was found to be safe and effective in an early stage human study. It effectively induced antibody formation in 67% of patients and T-cell responses in 75% to 100%...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics